MannKind | MNKD - Ebit


MannKind reported $-59.44M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
Adma Biologics USD 53.66M 5.57M Jun/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Eli Lilly USD 13.09B 635M Sep/2026
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Insmed USD -81.83M 19.48M Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -65.25M 33.36M Jun/2026
MannKind USD -59.44M 8.79M Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Novavax USD 20.94M 100.32M Dec/2025
Novo Nordisk DKK 5.25B 60.42B Jun/2026
Pfizer USD 4.85B 5.03B Sep/2026
Sanofi EUR 4.72B 3.6B Sep/2026
Xencor USD -36.6M 41.26M Jun/2026